RACK1 (receptor for activated C kinase 1) is an abundant scaffolding protein, which binds active PKCβII (protein kinase C βII) increasing its activity in vitro. RACK1 has also been described as a component of the small ribosomal subunit, in proximity to the mRNA exit channel. In the present study we tested the hypothesis that PKCβII plays a specific role in translational control and verified whether it may associate with the ribosomal machinery. We find that specific inhibition of PKCβI/II reduces translation as well as global PKC inhibition, but without affecting phosphorylation of mTOR (mammalian target of rapamycin) targets. These results suggest that PKCβII acts as a specific PKC isoform affecting translation in an mTOR-independent fashion, possibly close to the ribosomal machinery. Using far-Western analysis, we found that PKCβII binds ribosomes in vitro. Coimmunoprecipitation studies indicate that a small but reproducible pool of PKCβII is associated with membranes containing ribosomes, suggesting that in vivo PKCβII may also physically interact with the ribosomal machinery. Polysomal profiles show that stimulation of PKC results in an increased polysomes/80S ratio, associated with a shift of PKCβII to the heavier part of the gradient. A RACK1-derived peptide that inhibits the binding of active PKCβII to RACK1 reduces the polysomes/80S ratio and methionine incorporation, suggesting that binding of PKCβII to RACK1 is important for PKC-mediated translational control. Finally, down-regulation of RACK1 by siRNA (small interfering RNA) impairs the PKC-mediated increase of translation. Taken together the results of the present study show that PKCβII can act as a specific PKC isoform regulating translation, in an mTORindependent fashion, possibly close to the ribosomal machinery.
INTRODUCTION
Translation requires at least 11 eIFs (eukaryotic initiation factors) controlling the rate and accuracy [1] . The global initiation rate is controlled by signalling on the eIF4F complex, regulating capdependent translation, and on the eIF2 complex, bringing the ternary complex (tRNA i Met , eIF2 and GTP) on the 40S subunit [2] . The most studied stimulatory pathway on translation is through mTOR (mammalian target of rapamycin) kinase that acts on the formation of the cap complex, by the phosphorylation of the negative regulator 4E-BP1 (eIF4E-binding protein 1) [3, 4] . The mTOR pathway is activated by growth factors and optimal nutrient conditions. However, in most cells mTOR inhibition by rapamycin blocks only 15 % of the translation rate [5] , suggesting that other pathways parallel to mTOR may be important. For instance, stimulation of translation by adhesion to the extracellular matrix is totally independent from mTOR activation [6] , and translational recovery after hypertonic stress requires ERK1/2 (extracellular-signal-regulated kinase 1/2) signalling [7] . Thus dissecting mTOR-independent pathways is of major importance in order to fully grasp the complexity of translational regulation.
The PKC (protein kinase C) superfamily includes different isoforms that are involved in most cellular processes, including cell-cycle control, differentiation and apoptosis. In mammals, 11 PKC isoforms exist, divided into three subgroups on the basis of their responsiveness to general PKC activators [8] . Conventional PKCs (PKCα, PKCβI/II, PKCγ ) require both DAG (diacylglycerol) and Ca 2+ for activation. They can also be activated by phorbol esters, such as PMA, in a Ca 2+ -dependent manner. Novel PKCs (PKCδ, PKCε, PKCη, PKCθ ) are DAG/PMA sensitive but do not respond to Ca 2+ . Finally, atypical PKCs (PKCζ and PKCι/λ) are unresponsive to DAG and Ca 2+ and are activated by interaction with other signalling proteins.
PKCs have long been thought to be involved in translational control, on the basis of the observation that, in general, PKC stimulation by pharmacological agents leads to increased translation [9] . In principle, PKC-mediated control of translation can either be due to activation of pathways upstream of initiation factors, namely through the PI3K (phosphoinositide 3-kinase)/ Akt/mTOR and MAPK (mitogen-activated protein kinase)/S6K (S6 kinase) pathways [10] , or to the direct phosphorylation of initiation factors and ribosome-associated proteins. As an example of indirect activation of the translational machinery, PKCη acts both on the activation of the PI3K, mTOR cascade [11] and S6K phosphorylation [12] , therefore triggering eIF4F complex formation. Increased levels of eIF4F then stimulate capdependent translation. The direct phosphorylation of components of the translational apparatus by PKC is less clear-cut. Several reports have identified among initiation factors and ribosomeassociated factors, potential substrates of PKC in vitro, but their Abbreviations used: BCA, bicinchoninic acid; BMI, bisindolyl maleimide I; DAG, diacylglycerol; DTT, dithiothreitol; 4E-BP1, eIF4E-binding protein 1; eIF, eukaryotic initiation factor; ER, endoplasmic reticulum; ERK, extracellular-signal-regulated kinase; HEK, human embryonic kidney; MAPK, mitogenactivated protein kinase; mTOR, mammalian target of rapamycin; PI3K, phosphoinositide 3-kinase; PKC, protein kinase C; RACK1, receptor for activated C kinase 1; siRNA, small interfering RNA; S6K, S6 kinase; TCA, trichloroacetic acid; WD40, Trp-Asp 40.
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unequivocal demonstration in vivo is lacking. A case in point is eIF4E, which is efficiently phosphorylated by PKC in vitro [13] , and is found phosphorylated upon PKC activation in vivo [14] . However, knockout studies have shown that Mnk (MAPK interacting kinase)1 and Mnk2 are the kinases responsible in vivo [15] . Similarly, in vitro phosphorylation by PKC has been reported for the elongation factor eEF1 (eukaryotic elongation factor 1) [16] , and recently for other proteins associated with the translational machinery such as eIF6 [17] . This said, the issue of direct substrates of PKC on the ribosomal machinery in vivo is complicated by the existence of multiple differentially expressed PKC isoforms and by the fact that it is unclear whether PKCs and ribosome-associated substrates can be in close proximity. In this context, the requirement of membrane-derived DAG for PKC activation brings a positional constraint for the phosphorylation of ribosome-associated factors, and suggests that PKCs may act directly on the ribosomal machinery exclusively in the presence of adaptors or intermediate molecules, or in the proximity of membranes. It is therefore important to verify whether specific PKC isoforms can co-purify with ribosomes or membraneribosome complexes. One putative adaptor between PKC and ribosomes is RACK1 (receptor for activated C kinase 1). RACK1 is a conserved protein homologous with the β-subunit of heterotrimeric G-proteins. Its sequence contains seven internal WD40 (Trp-Asp 40) domains devoted to protein-protein interaction. WD40 domains are predicted to fold into a β-propeller structure, each domain forming a blade of the propeller [18, 19] . RACK1 has been identified as a receptor for PKC, after its activation by DAG and Ca 2+ [20] . Subsequent work has shown that the preferred PKC isoform(s) binding RACK1 are PKCβs [21] . The PKCβ locus generates two isoforms by alternative splicing, PKCβI and PKCβII. Both bind RACK1, although PKCβII at a higher affinity. Interestingly, PKCβII is highly expressed in the hypertrophic heart [22, 23] where translational rates are pathologically increased. RACK1 is very abundant and can function as a general adaptor molecule, binding other membrane-associated proteins such as Src kinase, integrin β1 and the NMDA receptor [24] .
Previous work in yeast and mammalian cells have demonstrated that RACK1 (Asc1p in yeast) binds the small ribosomal subunit in the cytosol [25] and mRNPs (micro-ribonucleoproteins) [26] . A similar situation has been observed in fission yeast, where Cpc2/RACK1 co-purifies with the small subunit [27] . RACK1 also binds eIF6 and, in vitro in the presence of PKC, can mediate the release of eIF6 from the ribosome [17] . These results suggested that RACK1 might function as a PKC adaptor on the ribosomal subunit. More recently, a cryo-EM (electron microscopy) map of the eukaryotic ribosome has shown that RACK1 is located in the proximity of the mRNA exit channel, in close contact with the binding surface of the eIF3 complex, and close to mRNA binding proteins [28] . Thus RACK1 may provide a platform allowing PKC translocation to ribosomes, and a subsequent direct action of PKC on the translational machinery.
In the present study we tested the hypothesis that RACK1 acts as a PKCβ kinase platform on ribosomes by: (i) defining the effect of the pharmacological inhibition of PKCβII on translation, (ii) characterizing the RACK1-PKCβII interaction on the ribosomal apparatus, (iii) studying the effect of inhibition of RACK1-PKCβII binding and (iv) studying the effect of exogenous PKCβII overexpression. The results show that PKCβII modulates the global translational rate and we provide evidence supporting a model in which the PKCβII-RACK1 interaction has a role in PKC-based stimulation, independent from mTOR.
MATERIALS AND METHODS

Reproducibility
All immunoprecipitations, metabolic assays and polysomal profiles were performed at least three times, with similar outcomes. For immunoprecipitations and polysomal profiles, representative experiments are shown.
Cell lines and treatments
HeLa and HEK (human embryonic kidney)-293 cells were cultured in DMEM (Dulbecco's modified Eagle's medium; Gibco) supplemented with 10 % (v/v) FBS (foetal bovine serum; Gibco), 1 % glutamine and a commercial antibiotic mix (Gibco). Transfections were carried out with either calcium phosphate (for HEK-293 cells) or Gene Porter transfection reagent (for HeLa cells) according to the manufacturer's protocol (Gene Therapy System). All stimulations were performed after 3-6 h of growth factor starvation. Cells were stimulated with 50 nM PMA and 100 nM insulin for 30 min, or pre-treated with 50 μM LY294002, 100 nM BMI (bisindolyl maleimide I), 5 μM hispidin or 50 nM rapamycin, 15 min before stimulation.
Drugs and reagents
The following antibodies were used: rabbit polyclonal antiphospho-Akt (Ser 473 ), anti-phospho-S6 (Ser 235/236 ) and anti-rpS6 (all from Cell Signaling); rabbit polyclonal isoform-specific anti-PKCβII (C-18; from Santa Cruz Biotechnology); mouse monoclonals anti-PKCε, anti-RACK1, anti-PKCβ (BD Transduction Laboratories), anti-KDEL (Stressgen) and anti-β actin (Sigma). A rabbit polyconal anti-4E-BP1 was a gift from Professor N. Sonenberg (Department of Biochemistry, McGill University, Montreal, Canada) [29] . A rabbit polyclonal anti-human β1 integrin was from Dr I. De Curtis (San Raffaele Scientific Institute, Milano, Italy) [30] . A rabbit polyclonal anti-rpS14 was from Dr T.-A. Sato (Columbia University, New York, NY, U.S.A.) [31] . The plasmid for PKCβII was a gift from Dr A. Newton (Department of Biomedical Sciences, University of California at San Diego, La Jolla, CA, U.S.A.) [32] . PMA, insulin (human, recombinant), and cycloheximide were from Sigma. The PKC inhibitor BMI, the PKCβ inhibitor hispidin, the mTOR inhibitor rapamycin and BSA were from Calbiochem. The PI3K inhibitor LY294002 was from Alexis Pharmaceuticals. RNasin ® was from Promega.
In vitro binding assay of PKCβII
The in vitro binding of PKCβII to ribosomes was performed as follows. Five pmol of purified ribosomal subunit 40S and 60S [33] and 10 ng of recombinant PKCβII and PKCε (Calbiochem) were applied to nitrocellulose membrane (Bio-Rad). The membrane was blocked for 1 h with 5 % (w/v) non-fat dried skimmed milk in PBS containing 0.05 % (v/v) Tween 20. Membranes were probed with 100 μl of lysate from HEK-293 cells, which had been diluted 1:1 with lysis buffer [50 mM Hepes/NaOH (pH 7.4), 100 mM NaCl, 30 mM MgCl 2 , 50 mM NaF, 100 mM 2-glycerophosphate, 1 mM DTT (dithiothreitol), 0.1 % Triton X-100, 0.1 % Tween 20 and protease inhibitor cocktail] containing 5 % (w/v) non-fat dried skimmed milk. This step was performed for 1 h at room temperature (25 • C). Further development of the blots was performed exactly as for standard Western blots.
The overlay assay of PKCβII with RACK1 was performed as previously described [20] with some modifications. Recombinant RACK1 (125 ng) was blotted on to nitrocellulose membrane (Schleicher and Schuell) using a slot-blot apparatus (Schleicher and Schuell). Unbound material was removed, and the membrane was incubated in overlay block [0.2 M NaC1, 50 mM Tris/HC1 (pH 7.5), 3 % (w/v) BSA and 0.1 % poly(ethylene glycol)] for 1 h at room temperature. In a separate tube, PKCβII (1 μg of purified recombinant SF9-expressed protein) was incubated in the presence of 50 μg/ml phosphatidylserine, 0.8 μg/ml DAG and 1 mM calcium in overlay buffer [50 mM Tris/HC1 (pH 7.4), 0.1 % BSA, 5 μg/ml leupeptin, 10 μg/ml soybean trypsin inhibitor, 0.1 % poly(ethylene glycol), 0.2 M NaC1, 0.1 mM CaC1 2 and 12 mM 2-mercaptoethanol] and in the presence or absence of the peptide. The mixture was incubated for 15 min while being rotated at room temperature and was then added to immobilized RACK1 for additional rotation for 15 min. Unbound material was removed, and the membrane was washed three times in overlay wash buffer [50 mM Tris/HC1 (pH 7.4), 0.1 % poly(ethylene glycol), 0.2 M NaC1, 0.1 mM CaC1 2 and 12 mM 2-mercaptoethanol]. Binding of PKCβII was detected using an anti-PKCβII polyclonal antibody followed by ECL ® (enhanced chemiluminescence; Amersham Pharmacia Biotech) and processed using the STORM system (Molecular Dynamics).
Polysomal profile and fraction analysis
A polysomal profile was performed as described [17] with some modifications. Cells were pre-treated for 10 min with 100 μg/ml cycloheximide and then scraped into 50 mM Tris/HCl (pH 7.4), 100 mM NaCl, 30 mM MgCl 2 , 0.1% Igepal, 100 μg/ml cycloheximide, 40 units/ml RNasin ® and protease inhibitor cocktail (Sigma). Whole cell extracts were clarified at 4
• C for 10 min at 15 000 g. The equivalent of 10 absorbance units at 254 nm were layered on to a 15-50 % sucrose gradient in 50 mM Tris/ acetate (pH 7.5), 50 mM NH 4 Cl, 12 mM MgCl 2 and 1 mM DTT and centrifuged at 4
• C in a SW41Ti Beckman rotor for 3.5 h at 39 000 rev./min. The absorbance at 254 nm was recorded by BioLogic LP software (Bio-Rad) and fractions were collected. Fractions were precipitated with 10 % TCA (trichloroacetic acid) according to standard protocol, separated on SDS/PAGE and analysed by Western blot. Densitometric analysis was performed by ImageQuant 5.0 software (Molecular Dynamics).
Permeabilization and metabolic assay
Subconfluent HEK-293 cells grown in 35 mm diameter plates were washed with 1 ml of ice-cold HBSS-H [137 mM NaCl, 5.4 mM KCl, 1.3 mM CaCl 2 , 1.03 mM MgSO 4 , 0.34 mM Na 2 HPO 4 , 0.44 mM KH 2 PO 4 , 5.6 mM glucose, 20 mM Hepes/ NaOH (pH 7.4)] and then treated for 1 min with 50 μg/ml saponin in 1 ml of ice-cold ICM buffer [125 mM KCl, 19 mM NaCl, 10 mM Hepes/KOH (pH 7.3), 0.33 mM CaCl 2 and 1.4 mM MgCl 2 ] without magnesium in the presence of 10 μM peptide. Cells were recovered for 5 min in 1 ml of ice-cold ICM buffer containing 10 μM peptide. Cells were incubated at 37
• C with serum-free medium for 2 h and with methionine-free medium for an additional 2 h. Cells were pulsed with 28 μCi per plate of Promix 35 S-labelled methionine (Amersham) and stimulated with 100 nM insulin and 50 nM PMA for 30 min. Cells were lysed by scraping into 50 μl of RIPA buffer without SDS [10 mM Tris/HCl (pH 7.5), 1 % sodium deoxycholate, 1 % Triton X-100, 150 mM NaCl, 1 mM EDTA and protease inhibitor cocktail]. Extracts of 10 μl were TCA-precipitated on glass microfibre filters (Whatman) and counted. Obtained values were normalized by sample protein content, quantified using the BCA (bicinchoninic acid) protein assay (Pierce). Each sample was analysed in triplicate and results are expressed as means + − S.E.M. Statistical analysis was performed by ANOVA.
Immunoprecipitation and Western blot
Adherent subconfluent HeLa and HEK-293 cells were lysed with 10 mM NaCl, 10 mM MgCl 2 , 10 mM Tris/HCl (pH 7.3), 1 % Triton X-100, 1 % sodium deoxycholate, 1 mM DTT, 5 mM NaF, 2 mM Na 3 VO 4 , 40 units/ml RNasin ® and protease inhibitor cocktail. The whole cell extract was clarified at 4
• C at 15 000 g for 10 min. The amount of protein recovered was quantified using the BCA protein assay. For immunoprecipitation, 3 mg of total proteins were pre-cleared with protein A beads (Amersham), and then incubated for 2 h at 4
• C with anti-PKCβII/anti-PKCβ or with an irrelevant antibody. Protein A beads were added and incubated for 1 h at 4
• C. The beads were washed four times with lysis buffer and resuspended in sample buffer. Immunoprecipitates were resolved on SDS/PAGE, transferred on to Immobilon-P membranes (Millipore) and probed with appropriate antibodies.
Spleen cells were derived from adult C57 mice as follows. Mice were killed according to the procedures approved by the IACUC (Institutional Animal Care and Use Committees), and spleens were immediately dissected out. Finely minced spleens were forced through a 40 μm-pore-size sieve cell strainer in serumfree RPMI medium (Gibco). Cells were spun down, washed in serum-free RPMI, lysed and immunoprecipitation was performed as described as above.
Phospho-protein detection was carried out in total lysates prepared in 20 mM Hepes (pH 7.4), 100 mM NaCl, 1 % sodium deoxycholate, 1 % Triton X-100, 2 mM Na 3 VO 4 , 50 mM NaF, 10 mM 2-glycerophosphate and protease inhibitor cocktail. The lysate was cleared by centrifugation (15 000 g for 10 min at 4
• C). Protein content was quantified with BCA as above. Equal amounts of proteins were analysed by Western blot.
Peptide design
The R7 peptide (RRFVGHTKDV) was designed on the RACK1 sequence binding PKCβII. The R9 peptide (GYTDNLIR-VWQVT) was derived from the seventh WD40 repeat of RACK1. Peptides were synthesized as previously described [34] . Both peptides used in the present study were over 90 % pure. Moreover, the R7 peptide was made twice (the second one from Calso Laboratory, Lyngby, Denmark), and each batch gave the same biological activities.
siRNA (small interfering RNA) transfection
The siRNAs targeted to human RACK1 were purchased from Ambion. The sequences are as follows: siRNA ID #135615 (siRNA1), 5 -CCAUCAAGCUAUGGAAUACTT-3 (sense) and 5 -GUAUUCCAUAGCUUGAUGGTT-3 (antisense); siRNA ID #135616 (siRNA2), 5 -GCUAUGGAAUACCCUGGGUTT-3 (sense) and 5 -ACCCAGGGUAUUCCAUAGCTT-3 (antisense); and siRNA ID #135617 (siRNA3), 5 -CCUUUACACG-CUAGAUGGUTT-3 (sense) and 5 -ACCAUCUAGCGUGUAA-AGGTG-3 (antisense). The siRNA negative control was purchased from Ambion (negative control siRNA #1). Cells (1.5 × 10 5 ) were seeded per plate (35 mm diameter) the day before transfection, and then transfected with 50 nM oligonucleotide using 2 μl of Lipofectamine TM 2000 reagent (Invitrogen). The siRNA/Lipofectamine TM mixture was prepared in Opti-MEM medium (Gibco) and was added to cells. After 5 h, normal growth medium was added to the cells. Protein expression was assessed by Western blotting at 48 h post-transfection and densitometric analysis was performed. A metabolic assay was carried out on siRNA-transfected cells as described above.
RESULTS
The PKCβ isoform can control the translational rate in an mTOR-independent fashion
In HEK-293 cells, PKC stimulation by PMA causes an increase of protein synthesis and phosphorylation of 4E-BPs [9] . Indeed, polysomal profile analysis of PMA-stimulated HEK-293 cells, always showed augmented polysomal peaks and reduced 80S, indicating an increase at the initiation step of translation ( Figure 1A) , accompanied by increased methionine incorporation ( Figure 1B) . To dissect the underlying PKC pathway, we applied BMI, a broad spectrum PKC inhibitor [35] or hispidin, an isoform-specific PKCβ inhibitor [36] . In conditions of stimulation, both PKC inhibitors caused decreased methionine incorporation ( Figure 1B) . Interestingly, PKCβ inhibition by hispidin repressed methionine incorporation as efficiently as global PKC inhibition, suggesting its isoform-specific involvement. The inhibition of either PKC or of mTOR had no effect on non-stimulated cells indicating that the effect we see is specific for the conditions of stimulation (see Supplementary Figure S1 at http://www.BiochemJ.org/bj/415/bj4150077add.htm).
Phorbol ester stimulation of all conventional PKCs causes activation of the ERK-S6K pathway and phosphorylation of 4E-BP1 [37] . Next we analysed the effect of global PKC inhibition and specific PKCβ inhibition on the phosphorylation status of 4E-BP1 and rpS6, which are downstream targets of mTOR and RSK/S6K [10] respectively. The broad PKC inhibitor BMI abolished PMA-stimulated rpS6 and 4E-BP1 phosphorylation ( Figure 1C, lane 5) , whereas the PKCβ inhibitor hispidin did not ( Figure 1C, lane 6) . Thus PKCβ isoform inhibition impairs translation without affecting the phosphorylation of mTOR targets. In agreement, the mTOR inhibitor rapamycin marginally repressed PKC-stimulated translation by PMA, whereas it repressed insulin-stimulated translation more effectively ( Figure 1D ). Taken together these results indicate that PKCβ affects translational efficiency, acting either downstream of the PI3K-Akt-mTOR axis or through a parallel pathway. Since PKCβ binds RACK1, one possibility is that PKCβ acts in proximity to ribosomes; thus we studied the relationship between PKCβ and ribosomes.
PKCβII associates with ribosomes
We first tested whether active PKCβII binds ribosomes directly. We spotted native 40S ribosomal subunits containing RACK1 or 60S subunits on filters, and performed binding with two PKC isoforms, βII and ε. PKCε is a PMA sensitive, Ca 2+ unresponsive PKC isoform that binds monomeric RACK1 [38] . We found that PKCβII specifically bound 40S subunits, but not 60S subunits, whereas PKCε bound neither of them (Figure 2A) .
We measured whether PKCβII may transiently interact with ribosomes in vivo. By analysing the polysomal profiles in unstimulated conditions little or no PKCβII was found to co-sediment with the part of the gradient containing rpS6 ( Figure 2B , lefthand panel). Upon PKC stimulation, we observed a reproducible shift of part of PKCβII towards fractions containing ribosomes ( Figure 2B , right-hand panel; compare RACK1-and rpS6-containing lanes). The increase in ribosome-associated PKCβII was 2-fold ( Figure 2C) , and was specific for PKCβII, since PKCε never co-sedimented with ribosomes ( Figure 2B ). Note that polysomal profiles were obtained in native conditions, without cross-linking, suggesting that the shift of PKCβII is comparable with the shift observed for some initiation factors [39] . This said, the absence of PKCβII from polysomes indicates that PKCβII is not retained during the elongation phase, whereas RACK1 is. (B) HEK-293 cells were treated as indicated and methionine incorporation was counted. The experiment was carried out in triplicate. PMA/insulin-mediated translation is inhibited both by the broad PKC inhibitor BMI and by the PKCβ-specific inhibitor hispidin (Hisp). (C) HEK-293 cells were treated as described and analysed for anti-phospho-Akt (an upstream factor in the insulin cascade stimulating translation), anti-4E-BP1 and anti-phospho-rpS6 (markers for mTOR and S6K1 activation respectively). Anti-rpS6 was used as a loading control. LY294002 (LY) inhibited PI3K/mTOR-dependent translation. Note that hispidin (Hisp) impairs translation without affecting the phosphorylation pattern of mTOR targets. (D) HEK-293 cells were treated as indicated and methionine incorporation was counted. Note that rapamycin inhibition does not impair PMA-dependent translation.
To further study the association of PKCβII with ribosomes, we immunoprecipitated endogenous PKCβII from unstimulated and PMA-stimulated cells, and tested for the presence of ribosomal proteins. PKCβII co-immunoprecipitated ribosomal protein rpS6 after stimulation ( Figure 2D ). The amount of PKCβII-co-precipitated ribosomal proteins was low, but detergent-resistant. The association of ribosomes with PKCβII was also observed in mouse tissues, e.g. in the mouse spleen, an organ containing high levels of the kinase ( Figure 2E ). The co-precipitation results
Figure 2 Endogenous PKCβII is associated to ribosomes
(A) Purified 40S and 60S ribosomal subunits were spotted on to nitrocellulose membrane. An overlay assay of PKCβII over immobilized ribosomes shows preferential association with the 40S subunit. Recombinant PKCβII and PKCε (a novel PKC isoform) were spotted as a control for isoform specificity of PKC antibodies. Note that increased staining of recombinant PKCs is due to their denaturation, whereas ribosomes and PKC on ribosomes are in the native form. showed that, in vivo, PKCβII has the potential to translocate to either ribosomes or ribosome-containing membranes. Since ribosomes can normally associate to ER (endoplasmic reticulum) membranes, reportedly even in the absence of ongoing transla- tion [40, 41] , we studied whether PKCβII activation resulted in translocation to membranes, including the ER. Indeed, PKCβII activation resulted in its translocation to endomembranes and the ER (see Supplementary Figure S2 at http://www.BiochemJ. org/bj/415/bj4150077add.htm and [42] ). Overall the results in Figures 1 and 2 lead to the hypothesis that PKCβII affects translation without acting on the mTOR pathway but preferentially interacts with the ribosomal machinery, either directly or through RACK1, or upon translocation to endomembranes.
The RACK1-PKCβII complex modulates translation
An important issue is to define whether the binding of PKCβII to RACK1 is instrumental to the PKCβII action on ribosomes and whether it may explain the localization of PKCβII on ribosomes. To investigate the significance of the PKCβII and RACK1 association on translation, we used a RACK1-derived peptide (R7), which mimics the RACK1-binding surface to PKCβII, and a control peptide (R9), which is designed on a RACK1 domain not involved in PKCβII binding. An in vitro binding assay of PKCβII on immobilized RACK1 showed that R7 inhibits the association between active PKCβII and RACK1 in a concentration-dependent manner, whereas R9 is ineffective (Figure 3) .
Polysomal profiles of cells treated with R7 peptide, which blocks PKCβII binding to RACK1, showed a reduction in polysomal peaks and less ribosome-associated PKCβII compared with R9 ( Figures 4A and 4B) , without obviously affecting the localization of RACK1. We also decided to approach the question as to whether the change in PKCβII distribution was associated with changes in methionine incorporation. Introduction of the R7 blocking peptide in HEK-293 cells caused a statistically significant reduction of PKC-stimulated translation, whereas R9 did not ( Figures 4C and 6C) . To further extend these results, we performed a series of experiments in which, after treatment with R7/R9 peptides, polysomal profiles were run, mRNA was extracted from polysomal fractions and was blotted for the presence of different mRNAs. We found that treatment with the R7 peptide reduced the polysomal association of several mRNAs (Supplementary Figure S3 at http://www.BiochemJ. org/bj/415/bj4150077add.htm), consistent with the effects on methionine incorporation.
Hispidin-based PKCβII inhibition caused a reduction in methionine incorporation without inhibition of mTOR activity. We tested whether R7-mediated impairment of translation caused an inhibition of mTOR activity. We found that R7 repressed translation ( Figure 4C ) without affecting rpS6 and 4E-BP1 phosphorylation ( Figure 4D , lane 5), in a similar manner to hispidin (see Figures 1B and 1C) . If RACK1 is important in mediating PKC effects, reduction of RACK1 by siRNA may also affect PKC-stimulated translation. We tested the hypothesis using RACK1 siRNA. A 70 % reduction in RACK1 expression by siRNA ( Figure 4E ) impaired the responsiveness to the PKCmediated increase in translation ( Figure 4F ).
Exogenously expressed PKCβII affects translation inhibited by RACK1-PKCβII disruption
Exogenous PKCβII recapitulated the results observed in HEK-293 cells. PKCβII was overexpressed in HeLa cells, which express negligible endogenous PKCβII ( Figure 5A ). The integrity and activation property of transfected PKCβII in overexpressing cells was tested by co-immunoprecipitation with RACK1 after activation ( Figure 5B) , and by phosphorylation of a specific PKC substrate [43] (results not shown). In HeLa cells overexpressing PKCβII, stimulation of PKCs resulted in increased cosedimentation of PKCβII with RACK1-containing fractions ( Figures 5C and 5D ). We immunoprecipitated overexpressed PKCβII and blotted for the endogenous ribosomal protein of the 40S subunit rpS14 ( Figure 5E ). A small, reproducible pool of rpS14 was associated with PKCβII, similar to that observed for rpS6 in HEK-293 cells. Exogenous overexpression of PKCβII led to increased methionine incorporation in newly translated proteins ( Figure 6A ), whereas mock and PKCι ( Figure 6B ) had no effect. Finally, we measured translation in cells overexpressing PKCβII by administration of either R7 or R9 peptides. As we observed in HEK-293 cells, the stimulation of PKC resulted in increased methionine incorporation in cells without peptides or in cells incubated with the R9 control peptide, but not in cells treated with the R7 peptide ( Figure 6C ).
DISCUSSION
One of the most studied pathways regulating translation is the mTOR-dependent pathway, which acts mainly through 4E-BP1 phosphorylation. However, as rapamycin-mediated block of mTOR and translation in most cells blocks only 15 % of translation, other pathways must exist. In the present study we have shown that PKCβII, at least in HEK-293 and HeLa cells, affects translation through an mTOR-independent pathway. Our results suggest that this pathway acts close to the ribosomal machinery through RACK1. The most consistent model explaining our results is that, upon activation, PKCβII fulfils its membrane requirement by translocating to endomembranes and then, through its interaction with RACK1, can come into physical contact with the translational apparatus. Alternatively, co-precipitation of PKCβII with ribosomes is due to the fact that they may both reside on membranes (see below).
Structural and biochemical studies have indicated that PKCβII binds RACK1 with nanomolar affinity, only after PKC activation [44] . The high affinity of binding, the high levels of RACK1 in cells, are consistent with the hypothesis that the RACK1-PKC complex can form in cells, in spite of the transient activation of PKC. The question is whether a RACK1-PKC complex can associate on the ribosome in vivo, and how stable it is. Several aspects must be taken in account. Although in vitro PKCβII binds RACK1 with high affinity, which in turn binds 40S, the detection of a stoichiometric interaction of PKCβII with ribosomes in vivo may be complicated by the kinetics of the interaction, possibly too rapid. Furthermore, PKCβII and ribosomes must be in equilibrium with endomembranes to allow PKC activation. Our model is that signalling to the translational machinery occurs at the interface between membranes and ribosomes, and RACK1 acts as a transient scaffold for PKC on the ribosome. In this context, we would like to suggest that the presence of endomembranes may be a general feature of translational control; for instance, the translational regulator mTORC1 [mTOR-raptor (regulatory associated protein of mTOR) complex] is detergentsensitive. In addition, work from the laboratory of Nicchitta [40, 41] suggests that most ribosomes are membrane-associated even when translation is blocked. Another alternative is that a specific pool of RACK1, not ribosome-bound, interacts with the activated PKCβII and then mediates a signal to the translational machinery. In this context the mixture RACK1-PKC is effective in mediating phosphorylation-dependent eIF6 release from 60S in vitro [17] .
A question to be addressed is which ribosome-associated substrates of RACK1-PKCβII may account for PKCβII-induced translational activation. One substrate that is phosphorylated by the RACK1-PKC complex is eIF6 [17] . However, the precise contribution of the activity of eIF6 in the control of the translational rate in vivo is still unclear, due to its pleiotropic action on ribosome biogenesis [45, 46] , although eIF6-knockout mice have a translation deficit downstream of PMA stimulation (V. Gandin, A. Miluzio and S. Biffo, unpublished work). Furthermore, PKC activation results in a strong increase in translation in conditions of overexpression of eIF6 [17] , and an increase in phosphorylated eIF6 [47] . As with most other kinases, it is likely that the RACK1-PKCβII complex may act on other substrates which remain to be characterized. Indeed, purified ribosomes show a sustained PKC-like activity (S. Grosso, V. Volta, M. Vietri, L.A. Sala, P.C. Marchisio and S. Biffo, unpublished work). Among the putative substrates, eIF4B has a PKC consensus sequence that is phosphorylated in vivo.
In conclusion, we provide evidence that a PKC isoform-specific pathway, alternative to the mTOR-4EBP1-S6K cascade, signals to the complex of initiation factors and mRNA-binding proteins acting on translational control. 
SUPPLEMENTARY ONLINE DATA
PKCβII modulates translation independently from mTOR and through RACK1
MATERIALS AND METHODS
Please see the Materials and methods section of the main text for the following methods: in vitro binding of PKCβII to ribosomes, polysomal profile, permeabilization and metabolic assay, immunoprecipitation, siRNA transfection. 
Indirect immunofluorescence
HEK (human embryonic kidney)-293 or HeLa cells were grown on human fibronectin-coated glass coverslips in a 24-well culture plate. Immunofluorescence was performed as previously described [1] . Confocal images were taken with the Ultra View 1 These authors contributed equally to the present study. 2 To whom correspondence should be addressed (email biffo.stefano@hsr.it). Confocal Imaging System (PerkinElmer) at the equatorial plane of the nucleus and were processed with Image-Pro Plus (The Proven Solution, version 4.5).
Membrane fractionation
Fractionation of membranes was obtained by centrifugation of extracts on a sucrose cushion as described previously [2] .
Northern blot analysis
Polysomal profiles were performed as described in the Materials and methods section of the main text and fractions were collected. RNA was extracted from each fraction by phenol/chloroform/ isoamylalcohol and Northern blot was performed as described by Sambrook and Russel [3] . Probes were prepared by Rediprime TM II (Amersham Biosciences) from PCR-amplified sequences through the following primers: 5 -ATGGAAGAAGAGATCGCCG-3 (forward) and 5 -TTAGAAGCATTTGCGGTGGA-3 (reverse) for γ -actin, 5 -TATTTCTACTGCGACGAGGA-3 (forward) and 5 -TGTTCTCGTCGTTTCCGCAA-3 (reverse) for c-myc, 5 -AAGGTCGGAGTCAACGGATT-3 (forward) and 5 -TCGTT-GTCATACCAGGAAATG-3 (reverse) for GAPDH (glyceraldehyde-3-phosphate dehydrogenase). The RACK1 (receptor for activated C kinase 1) sequence was derived from a vector kindly provided by Dr F. Loreni (Department of Biology, University of Vergata, Rome, Italy).
